Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Figure 3

Comparison of imaging findings in a patient who was diagnosed with advanced esophageal cancer with lung and liver metastases at the first visit and received sintilimab-based regimens. (a, c, e–g) Imaging findings before treatment with 2 cycles of sintilimab plus albumin-bound paclitaxel, nedaplatin, and palliative radiotherapy for esophageal tumors (5 March 2021). (b, d, h–j) Positron emission tomography-CT showed that all lesions and tumor metabolic activity disappeared after treatment (27 May 2021).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)